Vivek Ramaswamy On The Record
Vivek Ramaswamy NOT a “natural born Citizen” of the United States to Constitutional Standards – NOT Constitutionally Eligible to Be President and Commander-in-Chief of Our Military
https://thenewamerican.com/opinion/v...-be-president/
https://www.thepostemail.com/2023/07...-chief-of-our/
- Vivek Ramaswamy Paid Wikipedia Editors to Erase His Soros Fellowship and Covid Work
[SNIP]
Vivek Ramaswamy was born to immigrant parents from India August 9, 1985 in Cincinnati, Ohio. Religion: Hindu
Vivek Ramaswamy - Co-founder of Campus Venture Network (2007-2009); partner at hedgefund QVT Financial (2007-2014). Founder and CEO of Roivant Sciences Pharmaceutical Corporation (2014-2021); co-founder and executive chairman of Strive Asset Management (2022-present).
Vivek Ramaswamy: “I feel like I recoil when I see someone describe me as a conservative,” he told an interviewer. “Not that there’s anything wrong with being a conservative. It’s just not how I would describe myself.”
Vivek Ramaswamy: “I am taking the Trump America first agenda to the next level to actually get the job done,” he recently told a reporter https://indianexpress.com/article/wo...level-8475100/
PharmaVoice profiled Ramaswamy, noting that his calls for the United States to get tough on “Chinese business appear to be newly held, as two of Roivant’s subsidiaries during his time leading the company … notably focused on the innovations of medicine in China and for patients across Asia.
In its profile of Ramaswamy, Business Insider highlighted the fact that he “moonlighted as a rapper” while he was an undergraduate at Harvard.
Vivek Ramaswamy joined QVT Financial, where he slowly made a name for himself with a simple “buy low, sell high strategy.” In one notable example of this approach, he bought shares of the New Jersey-based Pharmasset in 2008 at $5 apiece, and then was a top shareholder by the time Gilead bought the company for $137 a share four years later.
Then, in 2014, he left QVT to found Roivant, backed by hedge fund QVT and an Israeli drug maker, with a goal to “reduce the average time and cost of the drug development process”. Roivant in 2016 disclosed a major investment from billionaire Andreas Halvorsen's Viking Global Investors hedge fund.
In a model Ramaswamy dubbed the “Berkshire Hathaway of drug development”, Roivant was designed to spin out smaller, highly focused subsidiary companies.
When one of the company’s first “vants” — Axovant — launched with what was at the time the biggest IPO in U.S. Biotech history (it’s now been surpassed by Moderna), Ramaswamy canceled his honeymoon to ring the bell at the New York Stock Exchange. During his tenure as CEO, a role he stepped down from in 2021, Ramaswamy oversaw the FDA approval of five medications.
To fight the fentanyl crisis, Ramaswamy said he would consider a “military assault” of Mexican drug cartels using airstrikes, drone attacks and special forces operations.
Despite his background in Pharma and recent debates over how the federal government should handle drug pricing, Ramaswamy has yet to release a policy platform on the issue, or other issues directly impacting the drug industry.
https://www.pharmavoice.com/news/viv...oivant/643559/
https://www.cfr.org/blog/meet-vivek-...tial-candidate
- In what should be a personal choice and between patient and private physician, Vivek posts the following concerning vaccines that have not been thoroughly and extensively tested. In response to the heading:
"Elites Now Have Extraordinary & Unchecked Powers", with Bill Gates in the background,
Vivek responds: "To state the obvious: we should aim to safely vaccinate everyone...
On the first day of trading the stock almost doubled, giving Axovant a market capitalization of nearly $3 billion. Considering that Ramaswamy had persuaded Glaxo to part with the unproven remedy for a mere $5 million up front, the newlyweds were ecstatic, as was a veritable wedding party of hedge fund pals who had followed Ramaswamy into the stock.
But this creeping fear ignores the full scope of what Ramaswamy is up to: rescuing the pharmaceutical industry’s forgotten drugs. Whether or not the Axovant drug works, the IPO, according to Ramaswamy, is just “a first step on a broader mission” to liberate abandoned or deprioritized drugs that routinely languish in the pipelines of pharma companies, never reaching patients or enriching investors.
Leaning on his Wall Street background and armed with a $400 million war chest, Ramaswamy is building a portfolio not of stocks but of has-been drugs that he grabs for “pennies on the dollar,” free-riding on the billions in research that pharma sometimes sinks into failed trials. Using a pharmaceutical holding company he formed last year, Roivant Sciences, Ramaswamy hopes to spin out dozens of companies, much as he did with Axovant. “This will be the highest return on investment endeavor ever taken up in the pharmaceutical industry,” he boasts. “It will be a pipeline every bit as deep and diverse as the most promising pharma company in the world but with a capital efficiency that is unprecedented.”
A whirlwind of such deals has made Ramaswamy, a member of the FORBES 30 Under 30 list, biopharma’s youngest chief executive. He may soon be its youngest billionaire. FORBES estimates that Roivant is worth $3.5 billion, making its Millennial founder’s 20% or so stake worth some $700 million. Ramaswamy, who just turned 30, has bigger aspirations. Roivant, he says, will become the “Berkshire Hathaway of drug development.”
https://www.forbes.com/sites/nathanv...h=a6ae9d54f392
- As a Biotech CEO Vivek Ramaswamy signed a letter supporting the “principles and best practices to increase gender diversity” in the life sciences industry, just five years later Ramaswamy became a mouthpiece against similar goals.
Vivek Ramaswamy cosigned a 2017 “Open Letter to the BioPharma Community” that includes an explicit commitment “to drive diversity as a top priority.”
Claiming that he is the “true outsider”:
Vivek Ramaswamy's Roivant Advisory Board
Kathleen Sebelius
Kathleen Sebelius previously served as U.S. Secretary of Health and Human Services (HHS) under Barack Obama, where she presided over 11 operating divisions, including the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health and oversaw the passage and implementation of the Affordable Care Act. Before that, she served as governor of Kansas.
https://theorg.com/org/roivant-scien...hleen-sebelius
https://www.marketscreener.com/busin...R-E/biography/
Tom Daschle
Senator Daschle is one of the longest serving Senate Democratic leaders in history and one of only two to serve twice as both Majority and Minority Leader. During his tenure, Senator Daschle navigated the Senate through some of its most historic economic and national security challenges. He served for three years as an intelligence officer in the U.S. Air Force Strategic Command. After military service, he spent five years as an aide to South Dakota Senator James Abourezk before seeking elected office. Senator Daschle is the Founder and CEO of The Daschle Group, A Public Policy Advisory of Baker Donelson. As a well-known expert on health policy reform, he has written two books: "Critical: What We Can Do About the Health-Care Crisis" and "Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform"
https://biography.omicsonline.org/un...daschle-967225
Olympia Snowe
Republican Senator Maine
Senate Armed Services Committee Subcommittee
Data, once present, is no longer present.
Vivek Ramaswamy's Roivant Advisory Board
Kathleen Sebelius
Kathleen Sebelius previously served as U.S. Secretary of Health and Human Services (HHS) under Barack Obama, where she presided over 11 operating divisions, including the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health and oversaw the passage and implementation of the Affordable Care Act. Before that, she served as governor of Kansas.
https://theorg.com/org/roivant-scien...hleen-sebelius
https://www.marketscreener.com/busin...R-E/biography/
Tom Daschle
Senator Daschle is one of the longest serving Senate Democratic leaders in history and one of only two to serve twice as both Majority and Minority Leader. During his tenure, Senator Daschle navigated the Senate through some of its most historic economic and national security challenges. He served for three years as an intelligence officer in the U.S. Air Force Strategic Command. After military service, he spent five years as an aide to South Dakota Senator James Abourezk before seeking elected office. Senator Daschle is the Founder and CEO of The Daschle Group, A Public Policy Advisory of Baker Donelson. As a well-known expert on health policy reform, he has written two books: "Critical: What We Can Do About the Health-Care Crisis" and "Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform"
https://biography.omicsonline.org/un...daschle-967225
Olympia Snowe
Republican Senator Maine
Senate Armed Services Committee Subcommittee
Data, once present, is no longer present.
- [Libertarian???] candidate Vivek Ramaswamy forgot that he voted for Libertarian Candidate Michael Badnarik in the 2004 election (did Vivek actually vote for Badnarik, or is the claim due to his presidential run?):
Ramaswamy notably asserted in two interviews released on June 30 and July 12 that he did not vote until 2020, when he backed former President Donald Trump over now-President Joe Biden.
- 2024 presidential candidate @VivekGRamaswamy tells @SymoneDSanders Ukraine is basically a client state of the United States, and he would require Putin to exit his military partnership with China.
VivekGR: Ukraine is a client state of the United States.
Reply With Quote
Originally Posted by oyarde
Connect With Us